Melinda E Sanders

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. pmc Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS
    Melinda E Sanders
    Department of Pathology, Vanderbilt University, Nashville, Tennessee 37232, USA
    J Proteome Res 7:1500-7. 2008
  2. ncbi request reprint Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies
    Melinda E Sanders
    Department of Pathology, Vanderbilt University Medical Center and Medical School, Nashville, TN 37232, USA
    Cancer 106:1453-61. 2006
  3. ncbi request reprint The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up
    Melinda E Sanders
    Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee 37232 5310, USA
    Cancer 103:2481-4. 2005
  4. pmc A multistage association study identifies a breast cancer genetic locus at NCOA7
    Kathryn S P Higginbotham
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Cancer Res 71:3881-8. 2011
  5. ncbi request reprint Excellent survival, cancer type, and Nottingham grade after atypical lobular hyperplasia on initial breast biopsy
    Bernadette K McLaren
    Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee 37232 2561, USA
    Cancer 107:1227-33. 2006
  6. pmc Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk
    William D Dupont
    Department of Biostatistics, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 2158, USA
    Cancer 116:8-19. 2010
  7. pmc Histologic associations and long-term cancer risk in columnar cell lesions of the breast: a retrospective cohort and a nested case-control study
    Fouad I Boulos
    Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Cancer 113:2415-21. 2008
  8. pmc Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification
    Justin M Balko
    Vanderbilt University Medical Center, 2200 Pierce Ave, 777 PRB, Nashville, TN 37232 6307, USA
    Mol Cancer Ther 11:2301-5. 2012
  9. pmc A multistage genetic association study identifies breast cancer risk loci at 10q25 and 16q24
    Kathryn S Higginbotham
    Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Cancer Epidemiol Biomarkers Prev 21:1565-73. 2012
  10. pmc Estrogen metabolism and exposure in a genotypic-phenotypic model for breast cancer risk prediction
    Philip S Crooke
    Department of Mathematics, Vanderbilt University, Nashville, TN 37232, USA
    Cancer Epidemiol Biomarkers Prev 20:1502-15. 2011

Collaborators

Detail Information

Publications27

  1. pmc Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS
    Melinda E Sanders
    Department of Pathology, Vanderbilt University, Nashville, Tennessee 37232, USA
    J Proteome Res 7:1500-7. 2008
    ..Several of the m/ z features used in the classifiers were identified by LC-MS/MS and two were confirmed by immunohistochemistry...
  2. ncbi request reprint Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies
    Melinda E Sanders
    Department of Pathology, Vanderbilt University Medical Center and Medical School, Nashville, TN 37232, USA
    Cancer 106:1453-61. 2006
    ..Radial scars (RS) are benign breast lesions that have been implicated as independent risk factors for invasive breast carcinoma (IBC)...
  3. ncbi request reprint The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up
    Melinda E Sanders
    Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee 37232 5310, USA
    Cancer 103:2481-4. 2005
    ..At the time the biopsies in the current study were originally examined, small DCIS was not diagnosed and, by default, these women were treated by biopsy only...
  4. pmc A multistage association study identifies a breast cancer genetic locus at NCOA7
    Kathryn S P Higginbotham
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Cancer Res 71:3881-8. 2011
    ..These observations provide consistent evidence that genetic variants at the NCOA7 locus may confer a reduced risk of breast cancer...
  5. ncbi request reprint Excellent survival, cancer type, and Nottingham grade after atypical lobular hyperplasia on initial breast biopsy
    Bernadette K McLaren
    Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee 37232 2561, USA
    Cancer 107:1227-33. 2006
    ..Nottingham grading, special tumor types, and survival after invasive cancer diagnosis were analyzed consistently for the first time...
  6. pmc Protein phosphatase 2A subunit gene haplotypes and proliferative breast disease modify breast cancer risk
    William D Dupont
    Department of Biostatistics, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 2158, USA
    Cancer 116:8-19. 2010
    ..Women who are diagnosed with benign proliferative breast disease are at increased risk for the subsequent development of breast cancer...
  7. pmc Histologic associations and long-term cancer risk in columnar cell lesions of the breast: a retrospective cohort and a nested case-control study
    Fouad I Boulos
    Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Cancer 113:2415-21. 2008
    ..However, the few retrospective outcome studies performed have failed to establish an increased risk for recurrence or carcinoma on long-term follow-up...
  8. pmc Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification
    Justin M Balko
    Vanderbilt University Medical Center, 2200 Pierce Ave, 777 PRB, Nashville, TN 37232 6307, USA
    Mol Cancer Ther 11:2301-5. 2012
    ..Second, they suggest that the role of activating mutations in RAS, although rare in breast cancer, may need to be explored in the context of ER+ breast tumors...
  9. pmc A multistage genetic association study identifies breast cancer risk loci at 10q25 and 16q24
    Kathryn S Higginbotham
    Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Cancer Epidemiol Biomarkers Prev 21:1565-73. 2012
    ..We conducted a multistage genetic association study in a series of independent epidemiologic breast cancer study populations to identify novel breast cancer risk variants...
  10. pmc Estrogen metabolism and exposure in a genotypic-phenotypic model for breast cancer risk prediction
    Philip S Crooke
    Department of Mathematics, Vanderbilt University, Nashville, TN 37232, USA
    Cancer Epidemiol Biomarkers Prev 20:1502-15. 2011
    ..Current models of breast cancer risk prediction do not directly reflect mammary estrogen metabolism or genetic variability in exposure to carcinogenic estrogen metabolites...
  11. ncbi request reprint A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer
    Dale S Cornett
    Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Mol Cell Proteomics 5:1975-83. 2006
    ..The higher performance characteristics offered by the new workflow promises to be a significant advancement toward the next generation of tissue profiling studies...
  12. pmc Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
    Brian D Lehmann
    Department of Biochemistry, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Clin Invest 121:2750-67. 2011
    ..These data may be useful in biomarker selection, drug discovery, and clinical trial design that will enable alignment of TNBC patients to appropriate targeted therapies...
  13. pmc Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance
    Justin M Balko
    Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University, Nashville, Tennessee, USA
    Nat Med 18:1052-9. 2012
    ..Thus, DUSP4 downregulation activates the Ras-ERK pathway in BLBC, resulting in an attenuated response to anti-cancer chemotherapy...
  14. pmc Heritable variation of ERBB2 and breast cancer risk
    Joan P Breyer
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 0275, USA
    Cancer Epidemiol Biomarkers Prev 18:1252-8. 2009
    ..In contrast, we observed no association of ERBB2 single nucleotide polymorphism haplotypes with breast cancer predisposition...
  15. pmc Molecular analysis of tumor margins by MALDI mass spectrometry in renal carcinoma
    Stacey R Oppenheimer
    Department of Biochemistry, Vanderbilt University, Nashville, Tennessee, USA
    J Proteome Res 9:2182-90. 2010
    ..This work demonstrates the utility of MALDI MS for the analysis of tumor tissue in the elucidation of aberrant molecular changes in the tumor microenvironment...
  16. doi request reprint Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers
    Marta Guix
    Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    J Clin Oncol 26:897-906. 2008
    ....
  17. pmc Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation
    Joshua A Bauer
    Departments of Biochemistry, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Clin Cancer Res 16:681-90. 2010
    ..To identify molecular markers of pathologic response to neoadjuvant paclitaxel/radiation treatment, protein and gene expression profiling were done on pretreatment biopsies...
  18. pmc Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets
    Justin M Balko
    Departments of 1Medicine, 2Pathology, Microbiology and Immunology, 3Cancer Biology, and 4Biochemistry 5Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee Departments of 6Cell and Tissue Biology and 7Medicine, University of California, San Francisco, San Francisco, California 8Foundation Medicine, Cambridge, Massachusetts 9Oncosalud and 10Instituto Nacional de Enfermedades Neoplásicas INEN, Lima, Peru
    Cancer Discov 4:232-45. 2014
    ....
  19. ncbi request reprint Direct analysis of laser capture microdissected cells by MALDI mass spectrometry
    Baogang J Xu
    Department of Chemistry, Vanderbilt University, Nashville, Tennessee, USA
    J Am Soc Mass Spectrom 13:1292-7. 2002
    ..The reported tissue preparation procedure and subsequent analysis by MALDI MS provide a new methodology for protein discovery involving LCM captured cells...
  20. pmc Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
    Ingrid A Mayer
    Ingrid A Mayer, Vandana G Abramson, Justin M Balko, María Gabriela Kuba, Melinda E Sanders, and Carlos L Arteaga, Vanderbilt University, Nashville, TN Steven J Isakoff, Massachusetts General Hospital, Boston, MA Andres Forero, University of Alabama, Birmingham, AL Jeffrey T Yap, Huntsman Cancer Institute, Salt Lake City, UT Annick D Van den Abbeele and Eric Winer, Dana Farber Cancer Institute, Boston, MA Yisheng Li, MD Anderson Cancer Center, Houston, TX and Lewis C Cantley, Weill Cornell Medical College, New York, NY
    J Clin Oncol 32:1202-9. 2014
    ..This phase Ib study evaluated buparlisib plus letrozole's safety, tolerability, and preliminary activity in patients with metastatic ER-positive breast cancer refractory to endocrine therapy...
  21. ncbi request reprint Can we know what to do when DCIS is diagnosed?
    Melinda E Sanders
    Department of Pathology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Oncology (Williston Park) 25:852-6. 2011
    ..Despite the 20-year-old dogma that all patients treated with breast conservation should receive postoperative radiation, a subset of patients who can be successfully treated by excision alone has been identified...
  22. pmc Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections
    Pierre Chaurand
    Mass Spectrometry Research Center, Department of Biochemistry, Vanderbilt University, Nashville TN, 37232 8575, USA
    Am J Pathol 165:1057-68. 2004
    ..The present article reviews the state of the art of the technology and its complementarity with traditional histopathological analyses...
  23. ncbi request reprint Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity
    Frederick Y Wu
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Cancer Res 66:2162-72. 2006
    ..These data suggest that cytoplasmic p27 can exert oncogenic functions by modulating Akt stability, cell survival, and tumorigenicity...
  24. pmc Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1
    Rebecca S Muraoka
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Mol Cell Biol 23:8691-703. 2003
    ....
  25. pmc Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling
    Vandana G Abramson
    Department of Medicine, Vanderbilt University School of Medicine, 2220 Pierce Ave, 777 PRB, Nashville, TN, 37232, USA
    Breast Cancer Res Treat 145:389-99. 2014
    ..PIK3CA mutation testing impacted treatment and resulted in more patients entering mutation-specific clinical trials. ..
  26. pmc Precision of multiple reaction monitoring mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue
    Robert W Sprung
    Jim Ayers Institute for Precancer Detection and Diagnosis, Vanderbilt Ingram Cancer Center, and Departments of Biochemistry, Pathology, and Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States
    J Proteome Res 11:3498-505. 2012
    ..The data further illustrate the feasibility of applying MRM to quantify clinically important tissue biomarkers in FFPE specimens. ..
  27. pmc Parameterizing the Logistic Model of Tumor Growth by DW-MRI and DCE-MRI Data to Predict Treatment Response and Changes in Breast Cancer Cellularity during Neoadjuvant Chemotherapy
    Nkiruka C Atuegwu
    Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN
    Transl Oncol 6:256-64. 2013
    ....